MoonLake Immunotherapeutics announced positive phase 3 data of patients with psoriatic arthritis treated with its lead nanobody candidate, sonelokimab.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
MoonLake Immunotherapeutics announced positive phase 3 data of patients with psoriatic arthritis treated with its lead nanobody candidate, sonelokimab.